Health News

Herceptin is the brand name of a medicine called trastuzumab. This medicine can stop the growth of breast cancer and sometimes reduce the size of the tumor. Herceptin is given by a drip into a vein. It can be given in combination with chemotherapy, or on its own to patients who have already had two courses of chemotherapy…

Read more

Filed under: Pharmacy News
Tags: Breast Cancer, cancer, medicine, Pharmacy, Tumor

Related posts

• What Is Herceptin (trastuzumab)? What Is Herceptin For? (0)
  Herceptin is the brand name of a medicine called trastuzumab. This medicine can stop the growth of breast cancer and sometimes reduce the size of the tumor. Herceptin is given by a drip into a vein. It can be given in combination with chemotherapy, or on its own to patients who have already had [...]
  
  
• Topline, interim results from Celldex Phase 2b EMERGE study of CDX-011 for advanced breast cancer (0)
  Celldex Therapeutics, Inc. today announced that interim, topline results of the Phase 2b EMERGE study of CDX-011 in patients with advanced breast cancer will be presented in a webcast on May 23, 2012. Linda Vahdat, MD, Professor of Medicine, Chief of Solid Tumor Service and Director of the Breast Cancer Research Program at Weill Cornell [...]
  
  
• Lapatinib plus trastuzumab extend lives of HER2-positive breast cancer patients (0)
  Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Center. Read more [tags] Pharmacy News [/tags]
  
  
• Combination therapy may overcome Herceptin-resistant breast cancer (0)
  Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment, scientists at The University of Texas MD Anderson Cancer Center report on line at Nature Medicine. Read more [tags] Pharmacy News [/tags]
  
  
• Anti-HER2 dendritic cell vaccine shows promise against DCIS (0)
  Researchers at the Perelman School of Medicine at the University of Pennsylvania report that a short course of vaccination with an anti-HER2 dendritic cell vaccine made partly from the patient's own cells triggers a complete tumor eradication in nearly 20 percent of women with ductal carcinoma in situ (DCIS), an early breast cancer. Read more [tags] Pharmacy [...]